Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2601 to 2650 of 2990 results for all

  1. What is the best and most cost-effective management strategy for people whose first surgery for primary hyperparathyroidism is not successful?

    preoperative imaging is to help guide the surgical approach. It is not essential in all circumstances (for example, if a decision has...

  2. Autism: register (IND175)

    This indicator covers establishing and maintaining a register of all patients on the autistic spectrum. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM153

  3. Rehabilitation: - What are the barriers to people with major trauma receiving early rehabilitation after rehabilitation assessment? What changes to services are needed to overcome these barriers?

    needs assessed, and that a rehabilitation prescription should be provided for all patients with rehabilitation needs. The rehabilitation...

  4. Pressure redistributing devices: Dopressure redistributing devices reduce the development of pressure ulcers for those who are at risk of developing a pressure ulcer?

    needed to identify what devices are beneficial for specific at-risk sites for all age groups. Source guidance details Comes from...

  5. How safe are drugs used to treat bipolar disorder in pregnancy and the postnatal period?

    effective for the acute treatment of bipolar disorder and for preventing relapse. All drugs used to treat mental health problems may...

  6. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (HTG423)

    Evidence-based recommendations on single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. This involves reducing the size of the stomach and small intestine to reduce the amount of food absorbed.

  7. MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes (MIB51)

    NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes

  8. Recognition and early management of pain in children and young people with cerebral palsy:- Does use of pain assessment tools by parents or carers improve the recognition and early management of pain in children and young people with cerebral palsy in a community setting?

    pain and discomfort outside hospital is of clear importance to help with all aspects of quality of life, including learning, development...

  9. Co-producing research into the views and experiences of people who use services:- What approaches have been shown to work in supporting the co-production of research for the purposes of service improvement with people who use services?

    who useservices is a potential means of improving services. Co-producing all stages of the research process with people who use services...

  10. What structure and organisation of specialist autism teams are associated with improvements in care for autistic people?

    There is uncertainty about the precise nature of the population to be served (all autistic people or only those who have an IQ of 70 or...

  11. Measuring improvements in care home residents' oral health:- How can interventions to improve and maintain oral health and wellbeing, or to prevent dental disease, be measured using a patient-centred approach that can also be used to judge cost effectiveness?

    to determine cost effectiveness. These measures would capture the views of all residents living in care homes and could include: - how...

  12. Anti-reflux therapy as a treatment for idiopathic pulmonary fibrosis:- Is anti-reflux therapy an effective treatment for idiopathic pulmonary fibrosis?

    mortality (allcause and idiopathic pulmonary fibrosis-related); hospitalisation (all-cause, non-elective and idiopathic pulmonary...

  13. What are the clinical and cost effectiveness, and the safety, of specific antifungal treatments for treating suspected or confirmed COVID-19-associated pulmonary aspergillosis (CAPA), and the optimal treatment duration? When should treatment be started, stopped or modified?

    amphotericin B deoxycholate. C: Standard care (usually voriconazole) O:• all-cause mortality (at any time during treatment)• number of...

  14. Jejunostomy support after radical surgery:- What is the effectiveness of long-term jejunostomy support compared to intensive dietary counselling and support along with symptom management for people having radical surgery for oesophago-gastric cancer?

    and not using them routinely and others not placing jejunostomy tubes at all. Studies should aim to identify if jejunostomy placement...

  15. Diabetes: annual care processes (IND10)

    This indicator covers the proportion of adults with diabetes who have received all 9 basic care processes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG13

  16. Rheumatoid arthritis: register (IND107)

    This indicator covers producing a register of all patients aged 16 years and over with rheumatoid arthritis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM55

  17. Reducing car ownership:- Does reducing car use or ownership change physical activity levels? Are effects maintained over time?

    asthe effects on different groups, and in different areas. For example not all areas have ready access to public transport; and for some...

  18. Predictors of acute physical risk:- What clinical and biochemical markers are the best predictors of acute physical risk for people with eating disorders?

    risk are used throughout this guideline. Despite their importance, almost all of the conventional risk frameworks are based on consensus...

  19. 5-aminosalicylate (5-ASA) treatment:- Following successful medical induction of remission of Crohn's disease of the colon, is mesalazine more clinically and cost effective than no treatment?

    question is applicable to adults, young people and children, and trials in all are therefore required. A conventional...

  20. What is the comparative effectiveness and cost effectiveness of exercise referral schemes compared with other interventions that aim to help people to become more physically active? Relative effectiveness and cost effectiveness should be compared in controlled trials.

    albeit below current UK physical activity guidelines rather than none at all, should be taken into account. (See the Department of...

  21. Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

    Evidence-based recommendations on darvadstrocel (Alofisel) for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn’s disease.

  22. Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (TA1046)

    Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.

  23. Inflammatory bowel disease (QS81)

    This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.

  24. Simple home test prevents thousands of unnecessary bowel cancer referrals

    A simple home test is sparing thousands of people from unnecessary hospital investigations for bowel cancer, while helping them get faster answers about whether they have the disease – with new data showing the impact of NICE's recommendation to use the test.

  25. Screening assessment tools:- Develop reliable and valid screening assessment tools for attachment and sensitivity that can be made available and used in routine health, social care and education settings.

    parents and foster or adoptive parents of children and young people across all groups (0–17 years).The tool must be readily available...

  26. Maternal request for caesarean birth: What support or psychological interventions would be appropriate for women who have a fear of vaginal childbirth and request a caesarean birth?

    lacking and could make a difference to women who are anxious or afraid. All of these interventions have different resource implications...

  27. Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to hospital?

    applicable) Why this is important:- Risk assessment is a mandatory for all people admitted or having day procedures in hospital. Since...

  28. t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes (MIB227)

    NICE has developed a medtech innovation briefing (MIB) on t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes .

  29. Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when used routinely or according to clinical need in children and young people who are at Gross Motor Function Classification System (GMFCS) level I, II or III?

    a strong recommendation to offer treatment with botulinum toxin type A to all children and young people who are at GMFCS level I, II or...

  30. Extended access to social care services:- What is the clinical and cost effectiveness of providing extended access to social care services, for example during early mornings and evenings, and 7 days a week?

    to social care differs throughout the country. Some areas have access to all socialcare services whereas others have very limited...

  31. Kidney conditions: AKI register (IND174)

    This indicator covers establishing and maintaining a register of all patients who have had an episode of AKI. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM152

  32. Cancer: register (IND250)

    This indicator covers the contractor establishing and maintaining a register of all cancer patients excluding non-melanotic skin cancers. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM234

  33. Heart failure: mortality within 12 months of admission (IND8)

    This indicator covers all-cause mortality within 12 months following a first emergency admission to hospital for heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG11

  34. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

    Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.

  35. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

    Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.

  36. Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable (TA1097)

    Evidence-based recommendations on enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable.